BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16396708)

  • 1. High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases.
    Cervetti G; Mechelli S; Riccioni R; Galimberti S; Caracciolo F; Petrini M
    Clin Exp Rheumatol; 2005; 23(6):877-80. PubMed ID: 16396708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.
    Arcaini L; Merli M; Passamonti F; Bruno R; Brusamolino E; Sacchi P; Rattotti S; Orlandi E; Rumi E; Ferretti V; Rizzi S; Meli E; Pascutto C; Paulli M; Lazzarino M
    Am J Hematol; 2010 Jan; 85(1):46-50. PubMed ID: 19957347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
    Hainsworth JD; Litchy S; Burris HA; Scullin DC; Corso SW; Yardley DA; Morrissey L; Greco FA
    J Clin Oncol; 2002 Oct; 20(20):4261-7. PubMed ID: 12377971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
    Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
    Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
    Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Auto-immune manifestations in Non-Hodgkin's lymphoma].
    Jardin F; Lévesque H; Tilly H
    Rev Med Interne; 2005 Jul; 26(7):557-71. PubMed ID: 15996570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
    Cartron G; Blasco H; Paintaud G; Watier H; Le Guellec C
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):43-52. PubMed ID: 17287129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus and lymphoma.
    Paydas S
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):246-56. PubMed ID: 25457774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
    Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
    Yang JD; Girotra M; Vaid A; Duarte-Rojo A
    J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rituximab and autoimmune disorders therapy].
    Quint L
    Rev Med Interne; 2004 Oct; 25(10):752-4. PubMed ID: 15471601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A; Keating MJ; Stasi R; Bradstock K
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.